Ceapro Inc V.CZO

RE:News????

[prophetoffactz]

"More studies and tests and trials that are at least several years from anything of signifcance..."

Phase I human clinical trials are significant and clinicaltrials.gov has an estimated timeline to completion of September 2024. Only 9-10 months away. Certain data read-outs could start being available very quickly given the timelines at clinicaltrials.gov for multiple metrics. Phase I generally is to address safety/tolerability in the context of the broader data on avenanthramide. A clean safety/tolerability profile could address the issue of colchicine(can be deadly, etc.) which recently set an FDA precedent as the first approved product to treat heart disease by addressing inflammation. The Dr., Dr. Jean-Claude Tardif, in charge of CZO's clinical trial was involved with that precedent-setting FDA approved drug. He also ran the largest out-patient clinical trial for COVID and CZO could address COVID heart inflammation.

With completion of the Phase I portion of the study CZO is already approved for a Phase IIa portion which could provide preliminary indications of efficacy. The biomarkers that need to be hit may be significantly understood given the understanding of inflammation and heart disease; including the first FDA approved drug. Having safety/tolerability and preliminary indications of efficacy for a drug already believed safe could be very signfiicant. Heart disease is a very large market.
 

"Pending successful results in the Phase 1 and potential Phase 2a study, we believe we will be well-positioned for out-licensing opportunities for later stage development and commercialization. With significant market potential and patient benefit, we believe avenanthramides is poised to be the biggest product for Ceapro,” concluded Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro." CZO news release

"Until now, people who suffered mild or asymptomatic COVID-19 were thought to have dodged the brunt of the virus’s brutal side effects. But new evidence has revealed that anyone infected with COVID is at higher risk for heart issues—including clots, inflammation, and arrhythmias—a risk that persists even in relatively healthy people long after the illness has passed." COVID and the Heart: It Spares No One | Johns Hopkins | Bloomberg School of Public Health (jhu.edu)